Drugs / Belrestotug
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05289492 | May 2022 → Nov 2023 | plasma cell myeloma | iTeos Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT05277051 | Mar 2022 → Aug 2027 expected | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04446351 | Jun 2020 → Dec 2026 expected | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04335253 | Feb 2020 → Apr 2022 | cancer of unknown primary site | iTeos Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05060432 | Sep 2021 → Jul 2024 | cancer of unknown primary site, head and neck cancer, lung neoplasm, melanoma | iTeos Therapeutics | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06062420 | Nov 2023 → Sep 2026 overdue | head and neck carcinoma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05565378 | Oct 2022 → Nov 2026 expected | non-small cell lung carcinoma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06926673 | Dec 2021 → May 2024 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03739710 | Jan 2019 → May 2024 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06472076 | Jun 2024 → Jun 2026 overdue | non-small cell lung carcinoma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-13 | GlaxoSmithKline | Results GSK provides update on belrestotug development programme gsk.com ↗
The decision is based on new interim analyses from the phase 2 GALAXIES Lung-201 and GALAXIES H&N-202 studies, which did not meet the established efficacy criteria for continued development. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-13 | GlaxoSmithKline | GSK provides update on belrestotug development programme gsk.com ↗ |
| 2021-06-14 | GlaxoSmithKline | GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations gsk.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | belrestotug | “EOS-448 (also known as GSK4428859A or belrestotug)” NCT05060432 ↗ |
| Known as | Clone 31282 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802205 ↗ |
| Known as | EOS-448 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05060432 ↗ |
| Known as | EOS884448 | “EOS884448 (EOS-448)” NCT05060432 ↗ |
| Known as | GSK4428859A | “EOS-448 (also known as GSK4428859A or belrestotug)” NCT05060432 ↗ |
| Known as | WB-2127 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802205 ↗ |
| Known as | WBP2127 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802205 ↗ |
| Action | Inhibit | “Anti-TIGIT monoclonal antibody” NCT05060432 ↗ |
| Modality | Monoclonal antibody | “Anti-TIGIT monoclonal antibody” NCT05060432 ↗ |
| Route | Intravenous | “Belrestotug will be administered as an IV infusion.” NCT04446351 ↗ |
| Target | TIGIT | “Anti-TIGIT monoclonal antibody” NCT05060432 ↗ |